Impact Biomedical IBO
NYSE IBO
$5.32 -0.14 (-2.56%)
At close: Oct 2, 2026 · 4:00 PM EDT

Impact Biomedical (IBO) Other Accumulated Expenses (2023 - 2026)

Updated

Impact Biomedical (IBO) reported Other Accumulated Expenses of $1.33 million for Q2 2026, up 20.6% from the prior quarter.

Analysis

Impact Biomedical (IBO) Other Accumulated Expenses (2023 - 2026) Analysis & Trends

At the end of FY2025, Impact Biomedical posted Other Accumulated Expenses of $621,000.

  • By year, Other Accumulated Expenses came in at $200,000 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Impact Biomedical 573.61 Mn 576.81 Mn 2,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.33 Mn
Mar 31, 2026 1.10 Mn
Dec 31, 2025 621,000.00
Mar 31, 2024 152,000.00
Dec 31, 2023 200,000.00
API Access

Impact Biomedical Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=IBO&period=max&api_key=YOUR_API_KEY